Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 5/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.51 |
| ▸ | MTOR | P42345 | 2/20 | 0.51 |
| ▸ | JAK2 | O60674 | 2/20 | 0.50 |
| ▸ | PLK4 | O00444 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | ROS1 | P08922 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
| ▸ | FLT1 | P17948 | 1/20 | 0.50 |
| ▸ | MARK3 | P27448 | 1/20 | 0.50 |
| ▸ | FLT4 | P35916 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | FLT3 | P36888 | 1/20 | 0.50 |
| ▸ | CLK2 | P49760 | 1/20 | 0.50 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.50 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.50 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.50 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20504089 | 0.94 | PIK3CA (0.48) | PIK3CAPIK3CDMTORJAK2PLK4 | |
| SCHEMBL18860575 | 0.86 | KDM4E (0.48) | PIK3CAPIK3CDJAK2PLK4MAP4K4 | |
| SCHEMBL18860531 | 0.84 | KDM4E (0.47) | PIK3CAPIK3CDJAK3SLC6A2SLC6A4 | |
| SCHEMBL7991106 | 0.84 | TTBK1 (0.56) | PIK3CAPIK3CDMTORJAK2TTBK1 | |
| SCHEMBL18860564 | 0.82 | MET (0.44) | PIK3CAPIK3CDMTORJAK2PLK4 | |
| SCHEMBL855738 | 0.82 | HTR3A (0.56) | FLT3MAP3K11RPS6KA3SLC6A2SLC6A4 | |
| SCHEMBL20504021 | 0.82 | SLC6A2 (0.44) | PIK3CAPIK3CDMTORJAK2PLK4 | |
| SCHEMBL5437082 | 0.82 | PLK4 (0.65) | PIK3CAPIK3CDMTORJAK2PLK4 | |
| SCHEMBL29652420 | 0.80 | PLK4 (0.58) | PIK3CAPIK3CDMTORJAK2PLK4 | |
| SCHEMBL27251926 | 0.80 | PIK3CD (0.46) | PIK3CAPIK3CDMAP3K11AKR1C3PIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743177-A1 | FLUORINATED AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | IPSEN PHARMA (FR) | 2026-05-20 | — | — | EP | disclosed |
| EP-4743084-A1 | AZAINDOLE DERIVATIVES WITH A CYCLO(HETERO)ALIPHATIC RING AND THEIR USE AS ERK KINASE INHIBITORS | IPSEN PHARMA (FR) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026087613-A1 | 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS, PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2026-04-30 | — | — | WO | disclosed |
| US-20260042758-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2026-02-12 | — | — | US | disclosed |
| EP-4588918-A1 | SYNTHESIS OF (S)-1-(1-(3-CHLOROPHENYL)-2-(DIMETHYLAMINO)ETHYL)- 4-(5-MORPHOLINO-1H-PYRROLO[2,3-B]PYRIDIN-3-YL)PYRIDIN-2(1H)-ONE | AGV Discovery (FR) | 2025-07-23 | — | — | EP | disclosed |
| WO-2025012383-A1 | AZAINDOLE DERIVATIVES WITH A CYCLO(HETERO)ALIPHATIC RING AND THEIR USE AS ERK KINASE INHIBITORS | IPSEN PHARMA (FR) | 2025-01-16 | — | — | WO | disclosed |
| WO-2025012357-A1 | FLUORINATED AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | IPSEN PHARMA (FR) | 2025-01-16 | — | — | WO | disclosed |
| EP-4463453-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery (FR) | 2024-11-20 | — | — | EP | disclosed |
| US-20240308997-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2024-09-19 | — | — | US | disclosed |
| CN-118541370-A | Azaindole derivatives and their use as ERK kinase inhibitors | AGV探索公司 | 2024-08-23 | — | — | CN | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| WO-2007002325-A1 | PYRROLO[2,3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002433-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060270646-A1 | Jnk inhibitors | EISAI CO., LTD. (JP) | 2006-11-30 | — | — | US | disclosed |
| WO-2004078756-A2 | JNK INHIBITORS | EISAI CO., LTD. (JP) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042758-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | BRAF, RAF1, NRAS | PIK3CA 337/4885PIK3CD 311/4885MTOR 140/4885 |
| US-20060270646-A1 | Jnk inhibitors | MAPKAPK2, MAPK1, MAPKAPK3 | PIK3CA 1960/4885PIK3CD 1836/4885MTOR 246/4885 |
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | PIK3CA 2108/4885PIK3CD 1866/4885MTOR 269/4885 |
| US-20240308997-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK7 | PIK3CA 405/4885PIK3CD 263/4885MTOR 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.